As the prevalence of obesity and diabetes increases globally, use of tirzepatide, a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has grown. Tirzepatide is described in the source as currently the most effective weight loss drug. The study aimed to identify reporting patterns in EudraVigilance related to suboptimal therapeutic outcomes and tirzepatide-related drug-use issues.
This was a retrospective pharmacovigilance study using descriptive and disproportionality analyses of individual case safety reports retrieved from the EudraVigilance (EV) database. The analysis focused on selected Preferred Terms (PTs) that reflect drug-use issues and suboptimal treatment outcomes. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated to compare tirzepatide with other GLP-1 receptor agonists.
The dataset comprised EV reports involving tirzepatide and comparator GLP-1 receptor agonists. Analyses were performed on the overall dataset (combining healthcare professional [HP] and non-HP reports) and separately for the HP-only subset. The outcome measures reported were RORs with 95% CIs for selected PTs related to drug-use issues.
Details such as the exact time frame covered, the total number of reports by drug, demographic breakdowns, and case-level narratives are not reported in the source article summary.
Among the selected PTs analysed, the most frequently reported terms for tirzepatide were Off-label use (n=1521), Drug ineffective (n=425) and Off-label use device (n=99). The source indicates that PTs reported by healthcare professionals generally showed lower reporting odds compared with non-healthcare professional reports.
In the overall dataset, tirzepatide reports showed lower reporting odds for the PT Drug ineffective compared with several other GLP-1 RAs:
For the PT Off-label use, a different pattern emerged in the full dataset. Tirzepatide had higher reporting odds compared with lixisenatide, dulaglutide and liraglutide, but showed lower reporting odds compared with semaglutide (ROR 0.52, 95% CI 0.49 to 0.55).
For the PT Off-label use device the overall reports showed a substantially higher reporting odd for tirzepatide versus semaglutide (ROR 43.47, 95% CI 16.00 to 118.13). The source cautions that this particular finding should be interpreted with caution given the wide confidence interval.
When analyses were restricted to reports submitted by healthcare professionals, PTs showed lower reporting odds compared with non-HP reports. Specifically, for the PT Drug ineffective, no difference in reporting odds was observed between tirzepatide and semaglutide in the HP-only subset. Additional HP-specific ROR values for other comparators or PTs are not provided in the summary.
The study used EV pharmacovigilance data to identify patterns of reported suboptimal therapeutic outcomes and drug-use issues for tirzepatide compared with other GLP-1 RAs. Key observations include high counts of reports coded as Off-label use and a measurable number coded Drug ineffective. Disproportionality analyses suggest lower reporting odds of 'Drug ineffective' for tirzepatide versus several other GLP-1 RAs in the combined dataset, whereas comparisons with semaglutide differ by reporter type (overall versus HP-only).
The markedly elevated ROR for Off-label use device versus semaglutide in the overall dataset is notable but has a very wide CI, which the authors advise interpreting cautiously.
The source describes the study as complementing evidence from clinical trials and clinical practice. As a pharmacovigilance analysis using EV, strengths include the ability to screen large numbers of spontaneous reports and to compare reporting patterns across drugs. Limitations inherent to spontaneous reporting systems apply, including under-reporting, reporting biases, variable report quality, and the inability to establish causality from disproportionality signals alone.
Specific methodological details such as the exact time window of data extraction, the total number of reports per drug, stratified demographic or clinical characteristics, and any case-level assessment or follow-up are not reported in the source summary.
This EV-based retrospective pharmacovigilance study identified reporting patterns for tirzepatide that included frequent PTs of Off-label use, Drug ineffective, and Off-label use device. Disproportionality analyses showed lower reporting odds for 'Drug ineffective' for tirzepatide versus several other GLP-1 RAs in the overall dataset, while some comparator relationships differed in healthcare professional reports. An elevated ROR for 'Off-label use device' versus semaglutide was observed but should be treated cautiously due to wide confidence intervals. The study authors state these findings complement existing clinical trial and practice evidence. Further details and case-level data were not reported in the source summary.